Argenx
ARGX
#535
Rank
C$59.61 B
Marketcap
C$960.49
Share price
-0.21%
Change (1 day)
13.12%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2025 (TTM): C$12.46

According to Argenx 's latest financial reports the company's current EPS (TTM) is C$12.32. In 2024 the company made an earnings per share (EPS) of C$19.34 an increase over its 2023 EPS that were of C-$7.17.

EPS history for Argenx from 2011 to 2025

Annual EPS

Year EPS Change
2025 (TTM)C$12.46-35.56%
2024C$19.34-369.77%
2023C-$7.17-60.46%
2022C-$18.1363.33%
2021C-$11.10-40.37%
2020C-$18.62183.47%
2019C-$6.57123.09%
2018C-$2.9454.93%
2017C-$1.9014.07%
2016C-$1.6713.05%
2015C-$1.47-36.34%
2014C-$2.31209.04%
2013C-$0.75-33.99%
2012C-$1.13185.59%
2011C-$0.40